A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II

Elsa G Shapiro, Kyle Rudser, Alia Ahmed, Robert D Steiner, Kathleen A Delaney, Brianna Yund, Kelly King, Alicia Kunin-Batson, Julie Eisengart, Chester B Whitley, Elsa G Shapiro, Kyle Rudser, Alia Ahmed, Robert D Steiner, Kathleen A Delaney, Brianna Yund, Kelly King, Alicia Kunin-Batson, Julie Eisengart, Chester B Whitley

Abstract

Objectives: The behavioral, adaptive and quality of life characteristics of attenuated mucopolysaccharidosis type II (MPS II) have not been well studied. Understanding changes over time in the attenuated phenotype may assist in helping achieve better outcomes in long-term function. This longitudinal study investigates these outcomes in relation to age, somatic disease burden, and IQ. Specifically, somatic disease burden is a major challenge for these patients, even with treatment with enzyme replacement therapy.

Methods: 15 patients, 10 between ages 6 and < 12 and 5 between ages ≥ 12 and 18, were selected who had at least 2 yearly visits. The occurrence of physical signs, the Physical Symptom Score, and IQ in these two groups was studied as well as the longitudinal association of age with standardized measures of quality of life, adaptive function, and behavioral symptoms as rated by parents and the child's self-report. Slopes by age across and within patients were calculated for these measures.

Results: All but one child had hearing loss, most had joint contractures and short stature. Somatic disease burden increased with age. IQ, although normal for most, also improved with age in those under 12 years of age. Physical quality of life decreased while psychosocial quality of life increased with age. Although other adaptive skills were in the broad average range, daily living skills were low at baseline relative to normative data and decreased over time. Behavior ratings indicated improvement in attention and hyperactivity over time. No patient had severe psychopathology, but older children reported an increasing sense of inadequacy and low self-esteem on self-report, presumably due to increasing awareness of differences from peers over time.

Conclusions: Attenuated MPS II patients have increasing somatic disease burden and poor physical quality of life as they develop as well as decreasing self-esteem and sense of adequacy. Psychosocial quality of life, adaptive skills, and attention improve. Recognition of and intervention around these issues will be beneficial to MPS II attenuated patients who have the resources to use such assistance to improve their long-term outcomes.

Keywords: Adaptive functions; Attenuated mucopolysaccharidosis type II; Behavioral outcomes; Quality of life.

References

    1. Martin R., Beck M., Eng C. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome) Pediatrics. 2008;121(2):377–386.
    1. Muenzer J., Beck M., Eng C.M. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124:e1228–e1239.
    1. Young I., Harper P., Newcombe R., Archer I. A clinical and genetic study of Hunter's syndrome. 2 differences between the mild and severe forms. J. Med. Genet. 1982;19(6):408–411.
    1. Yund B., Rudser K., Ahmed A. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II. Mol. Genet. Metab. 2015;114(2):170–177.
    1. Cross E.M., Hare D.J. Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J. Inherit. Metab. Dis. 2013;36:189–200.
    1. Marucha J., Jurecka A., Syczewska M., Różdżyńska-Świątkowska A., Tylki-Szymańska A. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 2012;101(4):e183–e188.
    1. Scarpa M., Almássy Z., Beck M. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J. Rare Dis. 2011;6(1):72.
    1. Schulze-Frenking G., Jones S.A., Roberts J., Beck M., Wraith J.E. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J. Inherit. Metab. Dis. 2011;34(1):203–208.
    1. Hollingshead A. Hollingshead; New Haven: 1957. Two Factor Index of Social Position.
    1. Wechsler D. Psychological Corporation; San Antonio TX: 1999. Wechsler Abbreviated Scale of Intelligence.
    1. Saklofske D.H., Caravan G., Schwartz C. Concurrent validity of the Wechsler Abbreviated Scale of Intelligence (WASI) with a sample of Canadian children. Can. J. Sch. Psychol. 2000;16(1):87–94.
    1. Ahmed A., Rudser K., Kunin-Batson A., Delaney K., Whitley C.B., Shapiro E. Mucopolysaccharidosis (MPS) specific physical symptom score: development, reliability and validity. J. Inherit. Metab. Dis. Rep. 2015
    1. Sparrow S.S., Cicchetti D.V., Balla D.A. second ed. Psychological Corporation; San Antonio, TX: 2005. Vineland Adaptive Behavior Scales.
    1. Landgraf J.M., Abetz L., Ware J.E. Health Institute, New England Medical Center; Boston: 1996. Child Health Questionnaire (CHQ): A User's Manual.
    1. Reynolds C.R., Kamphaus R.W. second ed. American Guidance Service; Circle Pines, MN: 2004. Behavior Assessment System for Children.
    1. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap) — a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009;42(2):377–381.
    1. R Core Team (2014). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URL /.
    1. Bax M.C., Colville G.A. Behaviour in mucopolysaccharide disorders. Arch. Dis. Child. 1995;73(1):77–81.
    1. Wraith J.E., Scarpa M., Beck M. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008;167:267–277.
    1. Holt J.B., Poe M.D., Escolar M.L. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011;127(5):e1258–e1265.
    1. Shimoda-Matsubayashi S., Kuru Y., Sumie H. MRI findings in the mild type of mucopolysaccharidosis II (Hunter's syndrome) Neuroradiol. 1990;32(4):328–330.
    1. Matheus M.G., Castillo M., Smith J.K., Armao D., Towle D., Muenzer J. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiol. 2004;13:666–672.
    1. Vedolin L., Schwartz I.V., Komlos M. Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. Am. J. Neuroradiol. 2007;28(6):1029–1033.
    1. Fan Z., Styner M., Muenzer J., Poe M., Escolar M. Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. Am. J. Neuroradiol. 2010;31(7):1319–1323.
    1. Manara R., Priante E., Grimaldi M. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. J. Inherit. Metab. Dis. 2011;34(3):763–780.
    1. Cho Y.S., Kim J.H., Kim T.W., Chung S.C., Chang S.A., Jin D.K. Otologic manifestations of Hunter syndrome and their relationship with speech development. Audiol. Neurootol. 2008;13(3):206–212.
    1. Nelson J., Carson D. Pituitary function studies in a case of mild Hunter's syndrome (MPS IIB) J. Med. Genet. 1989;26(11):731–732.
    1. A. Ahmed, E.G. Shapiro, K. Rudser, A. Kunin-Batson, C. B. Whitley. The association of somatic burden of disease with age and neuropsychological measures in MPS I, II and VI, (manuscript submitted for publication).
    1. Kato T., Kato Z., Kuratsubo I. Evaluation of ADL in patients with Hunter disease using FIM score. Brain Dev. 2007;29(5):298–305.
    1. Shapiro E., Nestrasil I., Rudser K. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol. Genet. Metab. 2015;116(1):61–68.
    1. Schwartz I.V.D., Ribeiro M.G., Mota J.G. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. 2007;455(Suppl. 96):63–70.
    1. Raluy-Callado M., Chen W.-H., Whiteman D.A., Fang J., Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J. Rare Dis. 2013;8(1):101.
    1. Needham M., Packman W., Quinn N. Health-related quality of life in patients with MPS II. J. Genet. Couns. 2015;24:635–644.
    1. Needham M., Packman W., Rappoport M. MPS II: adaptive behavior of patients and impact on the family system. J. Genet. Couns. 2014;23:330–338.
    1. Ahmed A., Whitley C.B., Cooksley R. Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the alpha-l-iduronidase gene in Hurler-Scheie syndrome. Mol. Genet. Metab. 2014;111(2):123–127.
    1. Bluechardt M.H., Wiener J., Shephard R.J. Exercise programmes in the treatment of children with learning disabilities. Sports Med. 1995;19(1):55–72.
    1. Maccoby E. Gender and relationships: a developmental account. Am. Psychol. 1990;45(4):513–520.
    1. Kirkcaldy B.D., Shephard R.J., Siefen R.G. The relationship between physical activity and self-image and problem behaviour among adolescents. Soc. Psychiatry Psychiatr. Epidemiol. 2002;37(11):544–550.
    1. Shephard R.J., Lavallée H., Larivière G. Competitive selection among age-class ice-hockey players. Brit J. Sports. Med. 1978;12(1):11–13.
    1. Ulrich B.D. Perceptions of physical competence, motor competence, and participation in organized sport: their interrelationships in young children. Res. Quarterly. 1987;58:57–67.
    1. Hanley G.P., Iwata B.A., McCord B.E. Functional analysis of problem behaviour, a review. J. Appl. Behav. Anal. 2003;36:147–185.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다